Search company, investor...

Achillion Pharmaceuticals

achillion.com

Founded Year

1998

Stage

Acq - P2P | Acquired

Total Raised

$110.65M

Valuation

$0000 

About Achillion Pharmaceuticals

Achillion is a biopharmaceutical company engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders.On January 28th, 2020, Achillion Pharmaceuticals was acquired by Alexion million.

Headquarters Location

300 George Street

New Haven, Connecticut, 06511,

United States

203-624-7000

Missing: Achillion Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Achillion Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Achillion Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Achillion Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Achillion Pharmaceuticals Patents

Achillion Pharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • Complement system
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/29/2019

9/20/2022

Complement system, Immune system, Immunology, Clusters of differentiation, Autoimmune diseases

Grant

Application Date

8/29/2019

Grant Date

9/20/2022

Title

Related Topics

Complement system, Immune system, Immunology, Clusters of differentiation, Autoimmune diseases

Status

Grant

Latest Achillion Pharmaceuticals News

Glomerulonephritis Treatment Market Is Anticipated To Register Around 5.4 % CAGR From 2022 To 2029

Nov 17, 2022

Glomerulonephritis Treatment Market Is Anticipated To Register Around 5.4 % CAGR From 2022 To 2029 Glomerulonephritis Treatment Market is expected to reach at a CAGR 5.4 % during the forecast period (2022-2029). Market.us has to return up with a brand new report specifically Global Glomerulonephritis Treatment Market standing and Outlook (2022-2031) that focuses on current trade updates, providing exclusive and analytical information through the span of 10 years. This report has been prepared by experienced and knowledgeable market analysts and researchers. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Glomerulonephritis Treatment market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the global market. Market.us Research analysts found that it has shown positive signs of growth since its inception. To view Top Players, Segmentation and other Statistics of Glomerulonephritis Treatment Industry, Get Sample Report:  https://market.us/report/glomerulonephritis-treatment-market/request-sample/   Note 1: Only Business E-mail id will be Prioritized Are You In Hurry? Then Check Out Below! Advantages of Using Our Report: – Identifying and analyzing the top players and their strategies. – Understanding the competitive landscape. – Identifying consumer insights. – You can strategize for entering the market. These market trends are examined with recently get table information relevant to the quantity of each market business and its market share. The Glomerulonephritis Treatment Market report reveals the size, share, trends, dynamics, growth, and sales also as a manufacturer, demand, revenue, consumption, current approaches, and art movement estimations. Also, involve distinct Glomerulonephritis Treatment business approaches accepted by the decision-makers. That intensifies Glomerulonephritis Treatment growth and makes a remarkable stand in the industry. The statistical study segregates the complete Glomerulonephritis Treatment market on the basis of key players, geographical areas, and segments. Initially, it figures out major Glomerulonephritis Treatment industry structures, guidelines, laws, regulations, and policies. Then provides projections of Glomerulonephritis Treatment market share, dynamics, and leading players. Later, it lineup a new Glomerulonephritis Treatment hypothesis to upgrade business values. In addition, it determines the Glomerulonephritis Treatment market status, present/future projects, growth rate, and consumption. It also reviews for world Glomerulonephritis Treatment market chain study, cost of raw material. Moreover, it discloses Glomerulonephritis Treatment downstream/upstream study and import-export detailing. Ensure everything is in line with your specific requirements here:  https://market.us/report/glomerulonephritis-treatment-market/#inquiry Exploring the market of Glomerulonephritis Treatment Market companies This market has its roots in North America, South America and majors in EMEA and APAC. Even though this market is a pretty new one, it is being dominated by the following organizations: Buy this report to learn about the latest business trends that are been adopted by the current players in the market. Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Market: Region Segment Analysis On the basis of geography, the global Glomerulonephritis Treatment market region is segmented into North America, Latin America, Asia-Pacific excluding Japan (APEJ), Eastern Europe, Western Europe, Middle East & Africa (MEA), and Japan. Among these regions, North America is presently leading the global Glomerulonephritis Treatment market. Along with North America, the Asia Pacific Glomerulonephritis Treatment market is projected to grow at a significant rate during the forecast period due to major investments. The demand for Glomerulonephritis Treatment is also anticipated to register high growth in global hubs such as Europe and Latin America region. Grab the full detailed report here:  https://market.us/report/glomerulonephritis-treatment-market/ Market Scope: #Trends:  The report discusses the many features that have an impact on the growth and future prospects of the Glomerulonephritis Treatment market. Positive factors that are influencing the market and restraining factors that are limiting its growth. They also discuss the impact on the global market. The market report also discusses other qualitative and quantitative factors, such as the risks involved in operations and the major challenges facing market key players. #Challenges: The study examines the major adoption trends in the Glomerulonephritis Treatment sector, as well as any issues that might hinder its growth. These elements are critical to product planning and design. This study provides an in-depth analysis of the trends and obstacles that exist in the Glomerulonephritis Treatment industry. #Statistics: The market size and share values of the Glomerulonephritis Treatment industry are provided in the report. It aids in understanding the market. Additionally, the report estimates upfront statistics and data that will be very useful to individuals involved in advertising and industry decision-making in the Glomerulonephritis Treatment. Reasons to buy – Find out how regulations or legal changes could affect the market – Identify market potential Q1. How big is the Glomerulonephritis Treatment market? Q2. What is the projected market size & growth rate of the Glomerulonephritis Treatment Market? Q3. What are the key driving factors for the growth of the Glomerulonephritis Treatment Market? Q4. What are the key trends in the Glomerulonephritis Treatment market report? Q4. What is the total market value of Glomerulonephritis Treatment market report? Q5. What segments are covered in the Glomerulonephritis Treatment Market Report? Q6. Who are the key players in Glomerulonephritis Treatment market? Q7. Which region has the highest growth in Glomerulonephritis Treatment Market? Trending Reports (Book Now with Save 25% [Single User], 38% [Multi-User], 45% [Corporate Users] + Covid-19 scenario+ Impact of Russia-Ukraine war):  – Market.us cover more than 15 major industries, segmented into more than 90 sectors. – More than 120 countries – More than 100 paid data sources were mined for investigation. – Ask our research experts any questions you may have before or after you purchase your report. – Develop an overview of the current Glomerulonephritis Treatment landscape in key markets – Learn how regulatory or legal changes will affect the market – Identify market prospects Gain Access to Our Comprehensive Library of Market Research Reports at Any Time, From Anywhere, and On Any Device. For More Details, Click the Following Secure Link:  https://market.us/report-library About Market.us Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons. We offer tactical and strategic support, which enables our esteemed clients to make well-informed business decisions and chart out future plans and attain success every single time. Besides analysis and scenarios, we provide insights into global, regional, and country-level information and data, to ensure nothing remains hidden in any target market. Our team of tried and tested individuals continues to break barriers in the field of market research as we forge forward with a new and ever-expanding focus on emerging markets. Communication contact: Market.us (Powered By Prudour Pvt. Ltd.)

Achillion Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Achillion Pharmaceuticals founded?

    Achillion Pharmaceuticals was founded in 1998.

  • Where is Achillion Pharmaceuticals's headquarters?

    Achillion Pharmaceuticals's headquarters is located at 300 George Street, New Haven.

  • What is Achillion Pharmaceuticals's latest funding round?

    Achillion Pharmaceuticals's latest funding round is Acq - P2P.

  • How much did Achillion Pharmaceuticals raise?

    Achillion Pharmaceuticals raised a total of $110.65M.

  • Who are the investors of Achillion Pharmaceuticals?

    Investors of Achillion Pharmaceuticals include Alexion, AstraZeneca Rare Disease, Quaker BioVentures, Domain Associates, Clarus, Pappas Ventures and 21 more.

  • Who are Achillion Pharmaceuticals's competitors?

    Competitors of Achillion Pharmaceuticals include Array Biopharma, ISTO Technologies, Cubist Pharmaceuticals, Alios BioPharma, Idenix Pharmaceuticals and 13 more.

Compare Achillion Pharmaceuticals to Competitors

REPLICor Logo
REPLICor

REPLICor is a biopharmaceutical company developing first-in-class entry inhibitors for the treatment of hepatitis C (HCV) and prevention of HCV re-infection following liver transplantation. The company also targets the hepatitis B and influenza markets. The lead compound REP 9AC is a broad-spectrum antiviral having potent activity against HCV, HBV, influenza and other enveloped viruses. The compound is active by multiple routes of administration and is well tolerated. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its product.

A
Arisyn Therapeutics

Arisyn Therapeutics Inc. is a biotechnology company focused on the development of first in class inhibitors of infectious disease and cancer. Arisyn possesses a portfolio of small molecule compounds that will be developed to treat Human Immunodeficiency Virus-Type 1 (HIV-1), Human Immunodeficiency Virus-Type 2 (HIV-2), Human T-Lymphotropic Virus-Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Herpes Simplex Virus-Type 2 (HSV-2). Arisyn will perform all necessary studies required to develop these therapeutic agents through Phase 1 and Phase 2 human clinical trials.

E
Elevation Biotech

Elevation Biotech specialises in the design and discovery of small peptide and peptidomimetic HIV attachment inhibitors. The company have developed biochemical and virological in vitro assays that screen specifically for the ability of compounds to block or interfere with viral attachment to the cell surface receptor CD4. The company's lead compound, is a short 7 amino acid peptide that binds to HIV envelope protein gp120 thereby preventing attachment of virus to the CD4 molecule.

I
Inflazyme Pharmaceuticals

Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.

M
Mimetica

Mimetica is a Brisbane-based biotechnology company which has developed a class of small molecule scaffolds that mimic reverse-turn motifs of peptides. These scaffolds have been used to create small molecule mimics of several important peptides and proteins known to be involved in the pathogenesis of disease. Mimetica is currently focusing its initial drug development activities on dermatological applications.

G
GangaGen

GangaGen is a biotechnology company focused on the development of products for the prevention and treatment of bacterial infections, particularly infections that are resistant to antibiotics, through the application of contemporary molecular and clinical sciences.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.